OROBOROS INSTRUMENTS GmbH

Their core work

Oroboros Instruments develops and manufactures high-resolution respirometry instruments (the O2k platform) used to measure mitochondrial function in cells and tissues. Their technology enables researchers and clinicians to assess cellular energy metabolism, which is critical for understanding diseases ranging from cancer to fatty liver disease to neurodegeneration. As an instrumentation SME, they sit at the intersection of biomedical research and diagnostic tool development, supplying precision equipment to labs across Europe while actively participating in the research networks that use their technology.

What they specialise in

How they've shifted over time

In their early H2020 period (2016-2018), Oroboros focused on applying their existing respirometry platform within disease-specific training networks — cancer (TRACT), tumorigenesis (TRANSMIT), and fatty liver disease (mtFOIE GRAS), with keywords emphasizing diagnostics, biomarkers, and metabolism. From 2018 onward, two shifts are visible: first, they invested heavily in next-generation instrument development through the SME Instrument pathway (Phase 1 → Phase 2, securing €1.65M for NextGen-O2k); second, their research scope broadened beyond mitochondria into organelle interactions, redox signalling, and systems biology (PERICO), while also entering neuroscience (FAT4BRAIN).

Oroboros is evolving from a niche respirometry supplier into a broader cellular analysis platform company, expanding both their instrument capabilities and the range of biological questions their technology addresses.

How they like to work

Oroboros primarily joins consortia as a specialist partner rather than leading them — 4 of 7 projects are as participant, with coordination limited to their own product development (NextGen-O2k). They work across a wide network of 55 partners in 17 countries, indicating they are sought after by many different research groups rather than embedded in a single consortium. This makes them an accessible, low-friction partner: they bring specific instrumentation expertise without competing for scientific leadership.

Broad European network spanning 55 unique partners across 17 countries, built through participation in large MSCA training networks. No single geographic cluster dominates — their instrument user base spans the continent.

What sets them apart

Oroboros occupies a rare position as an SME that both builds the instruments and participates in the research that uses them. This dual role — technology provider and scientific collaborator — means they understand researcher needs from the inside. Their successful SME Instrument Phase 1 → Phase 2 progression (50x funding increase) demonstrates strong commercial viability, making them a credible partner for projects that need both scientific depth and a path to market.

Highlights from their portfolio

• NextGen-O2k
  Successfully progressed from SME Instrument Phase 1 (€50k feasibility) to Phase 2 (€1.65M development) — their largest project and a clear commercial scale-up of their core technology.
• mtFOIE GRAS
  Large MSCA network tackling non-alcoholic fatty liver disease through mitochondrial profiling — directly links Oroboros instrumentation to a major public health challenge.
• PERICO
  Represents a scientific expansion beyond mitochondria into peroxisome biology and organelle interactions, broadening the application scope of their measurement platform.